Literature DB >> 24387883

Inflammation and vascularisation markers of arthroscopically-guided finger joint synovial biospies reflect global disease activity in rheumatoid arthritis.

Stefan Vordenbäumen1, Philipp Sewerin, Tim Lögters, Falk Miese, Christoph Schleich, Ellen Bleck, Paulina Philippski, Michael Schädel-Höpfner, Thomas Pauly, Matthias Schneider, Benedikt Ostendorf.   

Abstract

OBJECTIVES: To analyse whether synovial markers of the clinically dominant metacarpophalangeal (MCP) joint reflect global disease activity measures in rheumatoid arthritis (RA).
METHODS: Arthroscopically-guided synovial biopsies from the dominant metacarpophalangeal (MCP) joint of 10 patients with RA (DAS28 >3.2) were stained for determination of the synovitis score, CD68, vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1α (HIF-1α). MRI and ultrasound were used to calculate the RAMRIS and US7 score respectively. Arthroscopy of the same joint was repeated in 6 patients after 6 months.
RESULTS: The synovitis score significantly correlated to DAS28 (Spearman r=0.74), CRP (r=0.69), and US7 (r=0.66); sublining CD68 macrophages to CRP (r=0.6); HIF-1α to DAS28 (r=0.77), CRP (r=0.73); and VEGF to DAS28 (r=0.753) and RAMRIS (r=0.663). All patients showed a reduction of the DAS28 after 6 months (mean±SD: 5.2±1.5 vs. 2.75±1.1; p<0.05). There were three patients with a good EULAR response, and only these showed declining sublining CD68 macrophages in the control biopsy (χ2 test: LR 8.3, p=0.05). Two of the remaining patients with increasing CD68 sublining macrophages showed a deterioration of the RAMRIS.
CONCLUSIONS: Some histological findings in arthroscopically-guided biopsies of the dominantly affected MCP joint reflect global disease activity measures and their changes in RA patients. Moreover, repeated MCP synovial biopsy may distinguish true responders from individuals with residual disease activity, who are not readily recognized by clinical means.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24387883

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

1.  Intra-individual assessment of inflammatory severity and cartilage composition of finger joints in rheumatoid arthritis.

Authors:  C Schleich; A Müller-Lutz; P Sewerin; B Ostendorf; C Buchbender; M Schneider; G Antoch; F Miese
Journal:  Skeletal Radiol       Date:  2014-11-01       Impact factor: 2.199

2.  Dynamic contrast-enhanced magnetic resonance imaging of metacarpophalangeal joints reflects histological signs of synovitis in rheumatoid arthritis.

Authors:  Stefan Vordenbäumen; Christoph Schleich; Tim Lögters; Philipp Sewerin; Ellen Bleck; Thomas Pauly; Anja Müller-Lutz; Gerald Antoch; Matthias Schneider; Falk Miese; Benedikt Ostendorf
Journal:  Arthritis Res Ther       Date:  2014-10-01       Impact factor: 5.156

3.  Berberine ameliorates collagen-induced arthritis in rats associated with anti-inflammatory and anti-angiogenic effects.

Authors:  Zhigang Wang; Zhe Chen; Sisi Yang; Yu Wang; Zhaoyi Huang; Jianfei Gao; Shenghao Tu; Zhiguo Rao
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

4.  Six-month prospective trial in early and long-standing rheumatoid arthritis: evaluating disease activity in the wrist through sequential synovial histopathological analysis, RAMRIS magnetic resonance score and EULAR-OMERACT ultrasound score.

Authors:  Søren Andreas Just; Christian Nielsen; Jens Christian Werlinrud; Pia Veldt Larsen; Camilla Schufri Klinkby; Henrik Daa Schrøder; Fran Humby; Trine Torfing; Hanne Lindegaard
Journal:  RMD Open       Date:  2019-07-08

5.  Inhomogeneity of immune cell composition in the synovial sublining: linear mixed modelling indicates differences in distribution and spatial decline of CD68+ macrophages in osteoarthritis and rheumatoid arthritis.

Authors:  Johanna Mucke; Annika Hoyer; Ralph Brinks; Ellen Bleck; Thomas Pauly; Matthias Schneider; Stefan Vordenbäumen
Journal:  Arthritis Res Ther       Date:  2016-07-16       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.